Blueprint Medicines (BPMC) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Key growth drivers and commercial performance

• Ayvakit launch in indolent systemic mastocytosis (ISM) is a major focus, with strong revenue growth and raised sales guidance to $435M–$450M for the year.

• Large and expanding diagnosed patient pool, with increasing breadth and depth of physician prescribing and high patient compliance.

• Duration of therapy is expected to be multi-year, with positive patient experiences and smooth reimbursement access.

• International business, especially Europe, is contributing to growth, with Germany leading ISM commercial launch and ongoing pricing negotiations.

• Guidance reflects strong first-half performance, with expectations for steady growth, but accounting for potential seasonal and pricing impacts.

Market opportunity and competitive landscape

• ISM represents about 95% of the systemic mastocytosis market, with most of the peak sales opportunity coming from this segment.

• Ayvakit is the first therapy addressing the root cause of SM, building a strong leadership position with high barriers for future competitors.

• Disease awareness and education efforts are expanding the addressable patient pool, with advocacy groups playing a key role.

• Physicians are increasingly treating a broader spectrum of ISM patients, not just those with severe symptoms, due to recognition of long-term disease risks.

• Claims data show a significant progression rate from ISM to advanced SM, underscoring the need for early intervention.

Pipeline and R&D strategy

• Elenestinib, a next-generation KIT D816V inhibitor, is being advanced with a differentiated development strategy, targeting broader disease impact.

• Registrational work for Elenestinib is set to begin by year-end, with strategy updates expected.

• BLU-808, a wild-type KIT inhibitor, is in phase I healthy volunteer studies, with data expected early next year and chronic urticaria as the lead indication.

• BLU-808 aims to modulate mast cell activity in allergic and inflammatory disorders, leveraging Blueprint’s expertise in KIT biology.

• BLU-222, a selective CDK2 inhibitor, is being developed for hormone-positive, HER2-negative breast cancer, with ongoing partnering discussions and a degrader program in progress.